Stance Capital’s Idexx Laboratories IDXX Stock Holding History

Stance Capital’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Hold	400	–	–	0.11%	95
2025 Q4	$271K	Sell	400 -6,587	-94%	-$4.49M	0.1%	131
2025 Q3	$4.46M	Buy	6,987 +5,252	+303%	+$3.19M	1.64%	9
2025 Q2	$931K	Buy	+1,735	New	+$830K	0.35%	138
2025 Q1	–	Sell	-406	Closed	-$168K	–	156
2024 Q4	$168K	Buy	+406	New	+$178K	0.1%	110

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stance Capital's IDXX Position: Q1 2026 in Review

Stance Capital held its Idexx Laboratories (IDXX) position steady in Q1 2026 at 400 shares worth $225K. The position accounts for 0.11% of the portfolio, ranked #95.

Stance Capital first reported a position in IDXX in Q4 2024 and has held it in 5 quarters since. The position peaked at $4.46M in Q3 2025. 1,312 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Stance Capital held 400 shares of Idexx Laboratories worth $225K as of Q1 2026.
Stance Capital left its Idexx Laboratories share count unchanged in Q1 2026.
Idexx Laboratories made up 0.11% of Stance Capital's portfolio in Q1 2026, its #95 holding.
Stance Capital first reported a position in Idexx Laboratories in Q4 2024 and has held it in 5 quarters since.
Stance Capital's Idexx Laboratories position peaked at $4.46M in Q3 2025.
1,312 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Stance Capital's 13F filing for Q1 2026, filed 14 May 2026.